AtriCure (ATRC) Common Equity (2010 - 2026)

AtriCure (ATRC) has reported Common Equity for 17 consecutive years, with $516.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 11.18% year-over-year to $516.4 million in Q2 2026; TTM through Jun 2026 was $516.4 million, a 11.18% increase from a year earlier, with the FY2025 full-year figure at $491.9 million, up 6.72% from the prior year.
• Common Equity was $516.4 million for Q2 2026 at AtriCure, up from $491.7 million in the prior quarter.
• Over five years, Common Equity peaked at $516.4 million in Q2 2026 and troughed at $450.3 million in Q3 2022.
• A 5-year average of $467.4 million and a median of $462.6 million in 2022 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 18.6% in 2022, down 7.81% in 2022.
• Over 5 years, Common Equity stood at $456.8 million in 2022, then increased by 2.06% to $466.2 million in 2023, then retreated by 1.12% to $461.0 million in 2024, then rose by 6.72% to $491.9 million in 2025, then climbed by 4.98% to $516.4 million in 2026.
• The last three Common Equity figures came in at $516.4 million (Q2 2026), $491.7 million (Q1 2026), and $491.9 million (Q4 2025), per Business Quant data.